Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunitha Vimalesvaran

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
Human Reproduction (Oxford, England)|September 1, 2017
A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trialAli Abbara, Sophie Clarke, Rumana Islam, et al.
Human Reproduction (Oxford, England)|December 2, 2017
Reply: Clinical trial registry alone is not adequate: on the perception of possible endpoint switching and P-hackingAli Abbara, Sophie Clarke, Rumana Islam, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
Human Reproduction (Oxford, England)|September 1, 2017
A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trialAli Abbara, Sophie Clarke, Rumana Islam, et al.
Human Reproduction (Oxford, England)|December 2, 2017
Reply: Clinical trial registry alone is not adequate: on the perception of possible endpoint switching and P-hackingAli Abbara, Sophie Clarke, Rumana Islam, et al.
Pageof 4